

#### **Brandes Investment Partners**

U.S. Small Cap Value Equity Strategy Notes Fourth Quarter 2023 (October 1 – December 31, 2023)

The Brandes U.S. Small Cap Value Equity Strategy returned 7.50% net of fees and 7.72% gross of fees, underperforming its benchmark, the Russell 2000 Index, which gained 14.03% in the quarter, as well as the Russell 2000 Value Index, which was up 15.26%.

Annualized total return as of December 31, 2023	1-year	5-year	10-year
Brandes U.S. Small Cap Value Equity Composite (net)	22.58%	13.89%	9.52%
Brandes U.S. Small Cap Value Equity Composite (gross)	23.55%	14.90%	10.52%
Russell 2000 Index	16.93%	9.97%	7.15%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

# **Positive Contributors**

Despite a challenging start to 2023, the financials sector emerged as one of the best performers, driven partly by market optimism around an economic soft landing. A number of our financial holdings were leading contributors, notably insurers **Crawford & Company** and **Mercury General**, as well as banks **National Bankshares** and **Eagle Bancorp Montana**.

Aerospace and defense holdings **Embraer** and **Moog** also helped returns, with both companies continuing to see a resurgence in their end-markets.

Other standout performers included Avadel Pharmaceuticals, Elanco Animal Health, and software developer SolarWinds.

## **Performance Detractors**

Notable detractors included holdings in the health care sector, namely **Eagle Pharmaceuticals**, **Pediatrix Medical Group**, **Phibro Animal Health**, and **United Therapeutics**.

Eagle Pharmaceuticals declined after the company's founding chief executive abruptly resigned and Nasdaq issued a non-compliance notice related to its late quarterly earnings filing. The company had previously noted a delay in releasing its third-quarter results due to potential adjustments for reporting Pemfexy (a cancer treatment) sales.

Other detractors were energy companies **Dril-Quip** and **Chesapeake Energy**, aerospace-related firm **Park Aerospace**, outdoor sports company **American Outdoor Brands**, and wireless surveillance camera manufacturer **Arlo Technologies**. Additionally, our underweight to the financials sector weighed on returns relative to the benchmark.

### Select Activity in the Quarter

The small-cap investment committee initiated a position in **Spirit AeroSystems**, while selling its holding in **National Western Life Group**.

## Year-to-Date Briefing

The Brandes U.S. Small Cap Value Equity Strategy returned 22.58% net of fees and 23.55% gross of fees, outperforming its benchmark, the Russell 2000 Index, which was up 16.93% in 2023, and the Russell 2000 Value Index, which gained 14.65%.

The strongest contributors in 2023 were holdings in financials and industrials, led by insurers National Western Life Group and Crawford & Company, as well as industrial companies **Graham Corporation**, **L.B. Foster**, Embraer, Moog, and **Orion Group**. Beyond holdings in financials and industrials, Arlo Technologies and **Sprott Physical Uranium Trust** had solid returns.



Notable detractors were primarily in health care and energy, including Eagle Pharmaceuticals, **Premier**, Pediatrix Medical Group, and **World Kinect**. Other poor performers included **Netgear**, **Hurco Companies**, and **Hanesbrands**.

#### **Current Positioning**

The strategy maintained its largest weights in industrials, health care, and information technology (although underweight relative to the Russell 2000 Index). Over the course of 2023, there was a meaningful increase in our allocation to information technology, while the health care and industrials allocations were comparable to the start of the year.

Our most significant underweights were in consumer discretionary, financials, and real estate, which is consistent with how the portfolio was positioned to begin 2023 as well.

Compared with the Russell 2000 Value Index, we have significantly less exposure to financials and real estate. In our opinion, the differences between the Brandes U.S. Small Cap Value Equity Strategy and the broader U.S. small-cap market continue to make the strategy an attractive complement to other small-cap offerings. Our strategy exhibits lower valuations than the Russell 2000 Index while offering exposure to companies with what we consider strong balance sheets, compelling growth prospects and a history of durable free cash flow generation.

We are optimistic about the potential of value stocks in general and believe the Brandes U.S. Small Cap Value Equity Strategy remains well positioned from a long-term risk/reward perspective.

Term definitions: <a href="https://www.brandes.com/termdefinitions">https://www.brandes.com/termdefinitions</a>

The Russell 2000 Index with gross dividends measures the performance of the small cap segment of the U.S. equity universe.

The Russell 2000 Value Index with gross dividends measures performance of the small cap value segment of the U.S. equity universe. Securities are categorized as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or quaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a quarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

United States: Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

Singapore/Asia: FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

Canada: FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.